source
- Windward Bio raises $225 million in IPO to fund Chinese-sourced respiratory drug programWindward Bio, backed by Sanofi, completed its initial public offering at the $225 million target, selling 10.3 million shares at $17 each. The proceeds will be used to advance two respiratory drug…
- Regeneron's POTS antibody shows heart-rate reduction in Phase 2, paving way for Phase 3 trialRegeneron reported results from its Phase 2 Pinnacle trial of a monoclonal antibody targeting postural orthostatic tachycardia syndrome (POTS), a disorder with no approved therapies. The trial enr…